Obiettivo
RNA virus infections kill millions of humans annually, largely due to the lack of suitable vaccines and drugs to control them. This problem is addressed in this FP7 call and in response a consortium of Europe’s and Asia’s leading molecular virologists, structural biologists, medicinal chemists and bioinformaticians has been brought together to generate a state-of-the-art drug discovery and design programme. The project aims to identify Small molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER). It will focus its activities on selected medically important RNA viruses for which the development of drugs is considered essential (Dengue-, entero- and paramyxoviruses), whereas other relatively neglected and/or emerging RNA viruses will be explored to identify the most promising viral protein targets and antiviral compounds. A pipeline strategy has been developed to enable the inclusion in SILVER of viruses at all levels of existing knowledge. Targets for potential drugs include infectious virus, structurally characterised viral enzymes and other proteins. Leads for currently available antiviral drugs have been identified by screening compound libraries in virus-infected cell culture systems and in vitro assays using purified viral enzymes. Selective inhibitors of viral replication have also been (and are being) derived using detailed structural knowledge of viral proteins and structure-based drug design. Hits will be assayed using individual viral protein targets and replicative proteins in complex with viral RNA. The potential protective activity of the most potent inhibitors, that have a favourable (in vitro) ADME-tox profile, will be assessed in relevant infection models in animals. Licenses on promising compounds or compound classes will be presented to the interested pharmaceutical industry. The SILVER consortium will be well placed to play a major role in contributing to the international effort to develop strategies to improve world health.
Campo scientifico
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantivirals
Argomento(i)
Invito a presentare proposte
FP7-HEALTH-2010-single-stage
Vedi altri progetti per questo bando
Meccanismo di finanziamento
CP-IP - Large-scale integrating projectCoordinatore
13284 Marseille
Francia
Mostra sulla mappa
Partecipanti (23)
23562 Lubeck
Mostra sulla mappa
3000 Leuven
Mostra sulla mappa
2333 ZA Leiden
Mostra sulla mappa
3015 GD Rotterdam
Mostra sulla mappa
75724 Paris
Mostra sulla mappa
69120 Heidelberg
Mostra sulla mappa
Partecipazione conclusa
6525 XZ Nijmegen
Mostra sulla mappa
Partecipazione conclusa
01445 RADEBEUL
Mostra sulla mappa
OX1 2JD Oxford
Mostra sulla mappa
75794 Paris
Mostra sulla mappa
28006 Madrid
Mostra sulla mappa
CB2 8AL CAMBRIDGE
Mostra sulla mappa
Partecipazione conclusa
CH-8005 ZUERICH
Mostra sulla mappa
6020 Innsbruck
Mostra sulla mappa
20148 HAMBURG
Mostra sulla mappa
201203 SHANGHAI
Mostra sulla mappa
305606 DAEJEON
Mostra sulla mappa
320 Jhongli
Mostra sulla mappa
20122 Milano
Mostra sulla mappa
Partecipazione conclusa
04109 Leipzig
Mostra sulla mappa
3001 Heverlee
Mostra sulla mappa
3584 CS Utrecht
Mostra sulla mappa
14195 Berlin
Mostra sulla mappa